Source-grounded facts extracted from Kiniksa Pharmaceuticals International, plc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Kiniksa Pharmaceuticals International, plc shareholders approved Advisory approval of compensation of named executive officers at the 2026-05-29 meeting.
“Proposal 8 - To approve, on an advisory non-binding basis, the compensation of the Company’s named executive officers.”
Kiniksa Pharmaceuticals International, plc shareholders approved Approve UK Statutory Directors’ Remuneration Policy at the 2026-05-29 meeting.
“Proposal 7 - To approve the Company’s UK Statutory Directors’ Remuneration Policy.”
Kiniksa Pharmaceuticals International, plc shareholders approved Advisory approval of UK Statutory Directors’ Annual Remuneration Report for period ended December 31, 2025 at the 2026-05-29 meeting.
“Proposal 6 - To approve, on an advisory non-binding basis, the Company’s UK Statutory Directors’ Annual Remuneration Report for the period ended December 31, 2025.”
Kiniksa Pharmaceuticals International, plc shareholders approved Receive UK statutory annual account and report for period ended December 31, 2025 at the 2026-05-29 meeting.
“Proposal 5 - To receive the Company’s UK statutory annual account and report for the period ended December 31, 2025.”
Kiniksa Pharmaceuticals International, plc shareholders approved Authorize board of directors, through audit committee, to determine PwC’s remuneration as UK statutory auditors at the 2026-05-29 meeting.
“Proposal 4 - To authorize the Company’s board of directors, through its audit committee, to determine PwC’s remuneration in its capacity as the Company’s UK statutory auditors until the close of its next Annual Meeting of Shareholders.”
Kiniksa Pharmaceuticals International, plc shareholders approved Ratify appointment of PwC as US independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-29 meeting.
“Proposal 3 - To ratify the appointment of PwC as the Company’s US independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Kiniksa Pharmaceuticals International, plc shareholders approved Appointment of PricewaterhouseCoopers LLP as UK statutory auditors at the 2026-05-29 meeting.
“Proposal 2 - To approve the appointment of PricewaterhouseCoopers LLP (“PwC”) as the Company’s UK statutory auditors until the close of the Company’s next Annual Meeting.”
Kiniksa Pharmaceuticals International, plc shareholders approved Re-election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors at the 2026-05-29 meeting.
“Proposal 1 - The re-election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors to serve on the Board of Directors until the 2029 Annual Meeting of Shareholders”
Eben Tessari was appointed as special advisor to the Company's Science and Research Committee at Kiniksa Pharmaceuticals International, plc.
“Pursuant to a Consulting Agreement (the "Consulting Agreement") between Mr. Tessari and the Company, which will be effective as of May 15, 2026, Mr. Tessari will: (i) provide services to the Company related to strategic and operational matters and (ii) serve as a special advisor to the Company's Science and Research Committee (together, the "Services").”
Eben Tessari resigned as Chief Strategy Officer at Kiniksa Pharmaceuticals International, plc.
“On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the "Company") of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry.”
Kiniksa Pharmaceuticals International, plc reported the quarter ended March 31, 2026 results: revenue $214.3 million, net income $22.6 million. Guidance raised.
“--- Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected”
M. Cantey Boyd was appointed as Director at Kiniksa Pharmaceuticals International, plc.
“the appointment of M. Cantey Boyd, age 44, to the Board to fill the vacancy created thereby”
Kiniksa Pharmaceuticals International, plc reported first quarter 2024 results: revenue Total revenue for the first quarter of 2024 was $79.9 million, compared to $48.3 million for the first quarter of 2023., net income Net loss for the first quarter of 2024 was $17.7 million, compared to a net loss of $12.3 million for the first quarter. Guidance raised.
“On April 23, 2024, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.